– USA, NY – Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company today announced the appointment of Rene Salas to its Board of Directors.
“We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board. Rene’s extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innovative treatments to improve the lives of patients,” said Chairman and CEO, Dr. Sharon Mates.
Mr. Salas will also join the audit committee.
About E. Rene Salas
Rene Salas has over 35 years of experience with accounting and advisory projects in the life sciences and technology industries. From 1987 to 2019, Mr. Salas worked at Ernst & Young, LLP in a variety of roles, most recently as a senior client partner 2010 to 2019. At Ernst & Young LLP, Mr. Salas also served in various leadership roles on diversity, equity, and inclusion at the national and regional levels, including the firm’s national task force on DEI. From 2020 to 2022, he served as CFO of Wellstat, LLC, an early-stage biopharmaceutical company. He currently serves on the board of directors for Embody, Inc., a privately-held medical device company focused on soft tissue healing.
Mr. Salas received his B.B.A. in accounting from the University of Texas at San Antonio. He has also completed executive education programs in strategic leadership for Ernst & Young partners at Harvard Business School and Northwestern University’s Kellogg School. Mr. Salas is a Certified Public Accountant.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
For more information: https://www.intracellulartherapies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.